Praveen was most recently the President and CEO of Morphic Therapeutics Inc. where he led the company from its founding until the acquisition by Eli Lilly for $3.2 billion. Prior to founding Morphic, he served as Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals from 2006 until the company’s acquisition by Merck in 2015 for approximately $9 billion. Before this, Praveen was a member of the clinical group working on the Cubicin NDA (skin and skin structure infections) and sNDA (Staph. Bacteremia and Endocarditis), attributing to Cubicin hitting peak sales of $1.2 billion. Prior to joining Cubist, he worked at both Sun Microsystems and Covad Communications in Corporate Strategy, and at Deltagen in Business Development. He also served as a 1st Lieutenant in the U.S. Army.

Praveen received a BS degree from Massachusetts Institute of Technology (MIT) in Mechanical Engineering and an MD from McGill University. After completing his post-graduate residency in Internal Medicine at the University of Illinois, Chicago, he received his MBA in Healthcare Finance from the University of Pennsylvania’s Wharton School of Business.